Mycenax Biotech Inc. (4726) today hosted the 2026 Emerging Biologics Summit Asia, bringing together leading experts from Japan, China, and Taiwan to discuss the latest developments in antibody-drug conjugates (ADCs) and emerging biologics, including technological innovation, process development, CMC strategies, regulatory considerations, and global supply chain trends. The event attracted nearly one hundred participants from the biotechnology, pharmaceutical, investment, and academic sectors.
The summit also showcased Mycenax’s achievements in ADC contract development and manufacturing (CDMO). Through its proprietary technology platforms and strategic international partnerships, Mycenax has established an integrated, one-stop ADC development and manufacturing platform covering linkers, payloads, bioconjugation, drug substance (DS), and drug product (DP) manufacturing. The company continues to strengthen its dual-site strategy across Taiwan and Japan, building a more resilient global biologics supply chain.
In recent years, ADCs have become one of the fastest-growing therapeutic modalities in the global biopharmaceutical industry. As drug design and manufacturing become increasingly sophisticated, industry competition is evolving beyond individual technological breakthroughs toward comprehensive capabilities encompassing R&D, CMC, regulatory strategy, manufacturing excellence, and supply chain integration. With its end-to-end development capabilities, internationally recognized quality systems, and cross-border manufacturing footprint, Mycenax is well positioned to support the commercialization of next-generation therapeutics.
Focusing on ADC Innovation to Advance Next-Generation Therapeutics
The summit was moderated by Dr. Jui-Mei Lu, Director General of the Biomedical Technology and Device Research Laboratories at ITRI, and opened by Dr. Pei-Jiun Chen, Chairman and President of Mycenax.
Dr. Ping Yang Yeh, Managing Partner of NovaRadar Bio Venture, shared insights drawn from more than 30 years of experience in the global biotechnology industry, including leadership roles at Amgen, Biogen, and GSK. He discussed how, amid increasingly cautious capital markets, drug development is shifting toward value creation through greater efficiency. By leveraging platform technologies, strategic collaborations, and more efficient development models, companies can accelerate proof-of-concept studies, improve R&D success rates, and enhance capital efficiency. He also examined how evolving global policies are creating both new opportunities and challenges for the biotechnology industry.
Dr. Pei-Chin Tsai, Head of Pharmaceutical Development at Mycenax, introduced the company's integrated ADC development platform, demonstrating how Mycenax combines linker design, conjugation process development, analytical method development, and GMP manufacturing into a seamless service offering. The platform supports customers from early feasibility assessment through commercial manufacturing, helping shorten development timelines, reduce technology transfer risks, and accelerate product commercialization.
Dr. Yasuhiro Matsumura, founder of RIN Institute and a globally recognized expert in oncology and ADC research, presented his team's VLK linker technology, which significantly enhances targeted drug release within tumor tissues. He also introduced a next-generation ADC candidate jointly developed with Mycenax and Jian Yi Biotech, which demonstrated superior anti-tumor efficacy compared with current therapies in HER2-positive colorectal cancer patient-derived xenograft (PDX) models, highlighting the value of cross-border collaboration in advancing innovative therapeutics.
Dr. Yang Yang, Co-founder and Chief Executive Officer of Tangling Biotech, presented the company's proprietary site-specific conjugation technology platforms, explaining how they improve compatibility among antibodies, linkers, and payloads. These technologies have broad applications across ADCs, antibody-oligonucleotide conjugates (AOCs), and degrader-antibody conjugates (DACs), illustrating the future direction of next-generation conjugated therapeutics.
Connecting Key Asian Partners to Build an ADC Innovation Ecosystem
The summit concluded with a panel discussion moderated by Dr. Lu, featuring Dr. Chen, Dr. Yeh, Dr. Tsai, Dr. Matsumura, and Dr. Yang. The panel explored topics including ADC platform development, CMC strategies, global regulatory planning, commercialization of next-generation conjugation technologies, and the future of Asia's ADC innovation ecosystem.
The panelists agreed that the global ADC industry is entering a new era of platform integration, where future competitiveness will depend not only on breakthrough technologies but also on comprehensive strengths in CMC capabilities, regulatory strategy, supply chain resilience, and international collaboration.
The experts also noted that Asia is rapidly emerging as a major global center for biopharmaceutical innovation. Leveraging its strong biologics manufacturing expertise, well-established quality systems, and extensive regulatory experience, Taiwan is uniquely positioned to serve as a strategic CDMO hub connecting Asia with global markets.
From Taiwan to Japan, Connecting Asia with the World
Dr. Pei-Jiun Chen, Chairman and President of Mycenax, commented, "The global biopharmaceutical industry is undergoing a significant supply chain transformation, while the development of next-generation therapeutics increasingly depends on international collaboration and integrated platforms. Through this summit, Mycenax aims to establish a regional exchange platform that connects innovative technologies, manufacturing expertise, and strategic partners to accelerate the journey from research to commercialization."
She further noted that Japan represents one of the world's most important biopharmaceutical markets and one of Asia's most mature regulatory environments. Recent government initiatives promoting pharmaceutical supply chain resilience and localized manufacturing have further underscored the importance of regional production capabilities.
Mycenax will continue to position Taiwan as its core hub for development and manufacturing while actively advancing its manufacturing footprint in Japan. By establishing a dual-site operational model spanning Taiwan and Japan, the company combines Taiwan's strengths in process development, Japan's advantages in quality management, regulatory expertise, and market access, together with innovative technologies from global strategic partners, to build a more resilient global biologics supply chain and provide customers with more reliable and flexible CDMO services.
About Mycenax
Mycenax positions its Bio-CDMO brand around the core philosophy of "Big D, Strong M": Leveraging innovative development capabilities (D) and well-scalable manufacturing capacity (M), the company provides a fully integrated, one-stop shop for the development and manufacturing of both traditional and emerging biologics. Mycenax’s core value lies in its regulatory-compliant and highly market-competitive biologics development technologies and cGMP manufacturing facilities, seamlessly fulfilling the mission of bridging the gap between R&D achievements and pharmaceutical commercialization. With Taiwan as its central development and manufacturing hub, Mycenax integrates upstream and downstream industry chains to deliver comprehensive contract development and manufacturing services (CDMO).
Mycenax was established in September 2001, and current capital is NT$2.07 billion.
Stock Code: Mycenax (4726)
Official Website: http://www.mycenax.com
Press Contact:
Liru Yeh
Tel: +886-2-2655-8951 Ext. 6102
Email: liru.yeh@mycenax.com
Mycenax Biotech Inc. (4726) today hosted the 2026 Emerging Biologics Summit Asia, bringing together leading experts from Japan, China, and Taiwan to discuss the latest developments in antibody-drug conjugates (ADCs) and emerging biologics, including technological innovation, process development, CMC strategies, regulatory considerations, and global supply chain trends. The event attracted nearly one hundred participants from the biotechnology, pharmaceutical, investment, and academic sectors.
The summit also showcased Mycenax’s achievements in ADC contract development and manufacturing (CDMO). Through its proprietary technology platforms and strategic international partnerships, Mycenax has established an integrated, one-stop ADC development and manufacturing platform covering linkers, payloads, bioconjugation, drug substance (DS), and drug product (DP) manufacturing. The company continues to strengthen its dual-site strategy across Taiwan and Japan, building a more resilient global biologics supply chain.
In recent years, ADCs have become one of the fastest-growing therapeutic modalities in the global biopharmaceutical industry. As drug design and manufacturing become increasingly sophisticated, industry competition is evolving beyond individual technological breakthroughs toward comprehensive capabilities encompassing R&D, CMC, regulatory strategy, manufacturing excellence, and supply chain integration. With its end-to-end development capabilities, internationally recognized quality systems, and cross-border manufacturing footprint, Mycenax is well positioned to support the commercialization of next-generation therapeutics.
Focusing on ADC Innovation to Advance Next-Generation Therapeutics
The summit was moderated by Dr. Jui-Mei Lu, Director General of the Biomedical Technology and Device Research Laboratories at ITRI, and opened by Dr. Pei-Jiun Chen, Chairman and President of Mycenax.
Dr. Ping Yang Yeh, Managing Partner of NovaRadar Bio Venture, shared insights drawn from more than 30 years of experience in the global biotechnology industry, including leadership roles at Amgen, Biogen, and GSK. He discussed how, amid increasingly cautious capital markets, drug development is shifting toward value creation through greater efficiency. By leveraging platform technologies, strategic collaborations, and more efficient development models, companies can accelerate proof-of-concept studies, improve R&D success rates, and enhance capital efficiency. He also examined how evolving global policies are creating both new opportunities and challenges for the biotechnology industry.
Dr. Pei-Chin Tsai, Head of Pharmaceutical Development at Mycenax, introduced the company's integrated ADC development platform, demonstrating how Mycenax combines linker design, conjugation process development, analytical method development, and GMP manufacturing into a seamless service offering. The platform supports customers from early feasibility assessment through commercial manufacturing, helping shorten development timelines, reduce technology transfer risks, and accelerate product commercialization.
Dr. Yasuhiro Matsumura, founder of RIN Institute and a globally recognized expert in oncology and ADC research, presented his team's VLK linker technology, which significantly enhances targeted drug release within tumor tissues. He also introduced a next-generation ADC candidate jointly developed with Mycenax and Jian Yi Biotech, which demonstrated superior anti-tumor efficacy compared with current therapies in HER2-positive colorectal cancer patient-derived xenograft (PDX) models, highlighting the value of cross-border collaboration in advancing innovative therapeutics.
Dr. Yang Yang, Co-founder and Chief Executive Officer of Tangling Biotech, presented the company's proprietary site-specific conjugation technology platforms, explaining how they improve compatibility among antibodies, linkers, and payloads. These technologies have broad applications across ADCs, antibody-oligonucleotide conjugates (AOCs), and degrader-antibody conjugates (DACs), illustrating the future direction of next-generation conjugated therapeutics.
Connecting Key Asian Partners to Build an ADC Innovation Ecosystem
The summit concluded with a panel discussion moderated by Dr. Lu, featuring Dr. Chen, Dr. Yeh, Dr. Tsai, Dr. Matsumura, and Dr. Yang. The panel explored topics including ADC platform development, CMC strategies, global regulatory planning, commercialization of next-generation conjugation technologies, and the future of Asia's ADC innovation ecosystem.
The panelists agreed that the global ADC industry is entering a new era of platform integration, where future competitiveness will depend not only on breakthrough technologies but also on comprehensive strengths in CMC capabilities, regulatory strategy, supply chain resilience, and international collaboration.
The experts also noted that Asia is rapidly emerging as a major global center for biopharmaceutical innovation. Leveraging its strong biologics manufacturing expertise, well-established quality systems, and extensive regulatory experience, Taiwan is uniquely positioned to serve as a strategic CDMO hub connecting Asia with global markets.
From Taiwan to Japan, Connecting Asia with the World
Dr. Pei-Jiun Chen, Chairman and President of Mycenax, commented, "The global biopharmaceutical industry is undergoing a significant supply chain transformation, while the development of next-generation therapeutics increasingly depends on international collaboration and integrated platforms. Through this summit, Mycenax aims to establish a regional exchange platform that connects innovative technologies, manufacturing expertise, and strategic partners to accelerate the journey from research to commercialization."
She further noted that Japan represents one of the world's most important biopharmaceutical markets and one of Asia's most mature regulatory environments. Recent government initiatives promoting pharmaceutical supply chain resilience and localized manufacturing have further underscored the importance of regional production capabilities.
Mycenax will continue to position Taiwan as its core hub for development and manufacturing while actively advancing its manufacturing footprint in Japan. By establishing a dual-site operational model spanning Taiwan and Japan, the company combines Taiwan's strengths in process development, Japan's advantages in quality management, regulatory expertise, and market access, together with innovative technologies from global strategic partners, to build a more resilient global biologics supply chain and provide customers with more reliable and flexible CDMO services.
About Mycenax
Mycenax positions its Bio-CDMO brand around the core philosophy of "Big D, Strong M": Leveraging innovative development capabilities (D) and well-scalable manufacturing capacity (M), the company provides a fully integrated, one-stop shop for the development and manufacturing of both traditional and emerging biologics. Mycenax’s core value lies in its regulatory-compliant and highly market-competitive biologics development technologies and cGMP manufacturing facilities, seamlessly fulfilling the mission of bridging the gap between R&D achievements and pharmaceutical commercialization. With Taiwan as its central development and manufacturing hub, Mycenax integrates upstream and downstream industry chains to deliver comprehensive contract development and manufacturing services (CDMO).
Mycenax was established in September 2001, and current capital is NT$2.07 billion.
Stock Code: Mycenax (4726)
Official Website: http://www.mycenax.com
Press Contact:
Liru Yeh
Tel: +886-2-2655-8951 Ext. 6102
Email: liru.yeh@mycenax.com
